Amgen product sales slip but income stays steady
Net income at biotech giant Amgen stayed flat for the third quarter, despite a slight downtick in revenues to $5.8 billion, the company reported Oct. 25. Product sales saw a slight decline, including Neupogen, Epogen and its blockbuster rheumatoid arthritis drug Enbrel, which fell 6 percent, but net income stayed steady at a little more Read More →
Read More →Biotech giant Amgen to pay dividend on Dec. 8
Biotech giant Amgen announced Oct. 24 that it would pay a $1.15 dividend for its fourth quarter of fiscal 2017. Stockholders of record for the Thousand Oaks-based company at the end of day on Nov. 17 will receive the dividend on Dec. 8.
Read More →Westlake Village biotech company MannKind restructures debt
MannKind announced Oct. 23 that it had restructured debt due in 2018, exchanging $27.7 million in convertible notes for $23.7 million due in October of 2021 and nearly 1 million shares of its common stock. The new convertible senior subordinated exchange notes have a rate of 5.75 percent, the Westlake Village-based biotech company said in Read More →
Read More →Amgen studying genes to target pain conditions
For the next year, Amgen and Boston Children’s Hospital will use genetic analysis to study pain sensitivity. The biotech giant based in Thousand Oaks will work with patients who have abnormal pain conditions, and the hospital will validate genetic markers as potential targets for new therapies, the two announced in a press release on Oct. 16. “Traditional Read More →
Read More →
Amgen settles with AbbVie over Humira biosimilar litigation
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Marian Regional Medical Center expands health care options
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Oak Therapeutics touts study results for dissolvable strips
Oak Therapeutics, based in Oxnard, announced that it completed a study of the use of its dissolvable strips to administer an anti-tuberculosis treatment orally. A 300 milligram dose of isoniazid on the dissolvable strips given to canines entered the bloodstream at a statistically similar rate to commercial tablets, the study found. The company, a subsidiary Read More →
Read More →
Home of the Week
Sponsored Listing
Queen Anne Victorian Triplex, Santa Barbara
